doi: 10.1172/jci.insight.99123 [DOI] [PMC free article] [PubMed] [Google Scholar] 71
Companies with established GLP-1 franchises and manufacturing capabilities will capture the largest share of this rapidly expanding market through proven efficacy and safety profiles
This is the primary mechanism behind GLP-1-related constipation, and it is one of the most common complaints among users
Liraglutide stimulates endogenous insulin production while offering appetite suppression and cardiovascular protection
For most users, the effective loading dose ranges from 0.25mg to 0.5mg daily, with fair-skinned individuals (Fitzpatrick III) often requiring the higher end (0.50.75mg) to overcome low baseline melanocyte activity
Differences in kidney considerations, hypoglycemia risk, weight effects, side effects, and storage can be clinically meaningful